1-20 of 22
Michael A. Palladino
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells

Dharminder Chauhan, PhD, Ajita V. Singh, Arghya Ray, Ph.D, Teru Hideshima, MD, PhD, Paul G. Richardson, MD, Michael A. Palladino, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2011) 118 (21): 1841.
https://doi.org/10.1182/blood.V118.21.1841.1841
Published: 2011
Journal Articles

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Paul G. Richardson, MD, Andrew Spencer, MD, Paul Cannell, MBBS, FRCPA, FRACP, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Laurence Catley, MBBS, FRCPA, FRACP, Craig Underhill, MBBS, FRACP, Todd M. Zimmerman, MD, Craig C. Hofmeister, MD, Andrzej J Jakubowiak, MD, PhD, Jacob P. Laubach, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Ana Lay, Sandra Wear, RN, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Steve Reich, MD, Matthew A. Spear, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2011) 118 (21): 302.
https://doi.org/10.1182/blood.V118.21.302.302
Published: 2011
Journal Articles

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells

Ajita V. Singh, Madhavi Bandi, Noopur Raje, Paul Richardson, Michael A. Palladino, Dharminder Chauhan, Kenneth C. Anderson
Journal: Blood
Blood (2011) 117 (21): 5692–5700.
https://doi.org/10.1182/blood-2010-12-323857
Published: 2011
Journal Articles

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

Dharminder Chauhan, Ajita V. Singh, Bryan Ciccarelli, Paul G. Richardson, Michael A. Palladino, Kenneth C. Anderson
Journal: Blood
Blood (2010) 115 (4): 834–845.
https://doi.org/10.1182/blood-2009-03-213009
Published: 2010
Includes: Supplemental data
Journal Articles

Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis.

Stavroula Baritaki, Kam Yeung, Ph.D., Katherine Wu, Haiming Chen, MD, PhD, James R. Berenson, MD, Michael A. Palladino, PhD, Benjamin Bonavida, PhD
Journal: Blood
Blood (2009) 114 (22): 3938.
https://doi.org/10.1182/blood.V114.22.3938.3938
Published: 2009
Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Paul Richardson, M.D, Craig Hofmeister, MD, Andrzej Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Susan L. Kelly, MD, Saskia Neuteboom, PhD, Gillian F Cropp, MSc, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 431.
https://doi.org/10.1182/blood.V114.22.431.431
Published: 2009
Journal Articles

NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells.

Dharminder Chauhan, Ph.D, Ajita V. Singh, Madhavi Bandi, Noopur Raje, M.D., Robert L Schlossman, M.D., G. Kenneth Lloyd, PhD, Paul Richardson, Michael A. Palladino, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 3842.
https://doi.org/10.1182/blood.V114.22.3842.3842
Published: 2009
Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.

Andrew Spencer, Michael Millward, MD, Paul Mainwaring, MD, Simon Harrison, MD, Laurence Catley, MBBS, FRCPA, FRACP, Amanda Townsend, MD, Shawgi Sukumaran, MD, Angie M. Longenecker, RN, BSN, Michael A. Palladino, PhD, G. Kenneth Lloyd, PhD, Saskia Neuteboom, PhD, Peeter Padrik, MD, Matthew A. Spear, MD, Timothy Price, MD
Journal: Blood
Blood (2009) 114 (22): 2693.
https://doi.org/10.1182/blood.V114.22.2693.2693
Published: 2009
Journal Articles

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

Paul Richardson, MD, Craig C. Hofmeister, MD, Todd M. Zimmerman, MD, Asher Alban Chanan-Khan, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Sandra Wear, Alison L. Hannah, MD, Kenneth C Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 2770.
https://doi.org/10.1182/blood.V112.11.2770.2770
Published: 2008
Journal Articles

The Novel Proteasome Inhibitor NPI-0052 Induces the Expression of Raf-1 Kinase Inhibitor Protein RKIP) in B-NHL via Inhibition of the Transcription Repressor Snail: Roles of Snail and RKIP in Sensitization to TRAIL Apoptosis

Stavroula Baritaki, Aaron Chapman, Katherine Wu, Kam Yeung, Ph.D., Demetrios Spandidos, Ph.D., James R. Berenson, MD, Michael A. Palladino, MS, PhD, Benjamin Bonavida, PhD
Journal: Blood
Blood (2008) 112 (11): 2611.
https://doi.org/10.1182/blood.V112.11.2611.2611
Published: 2008
Journal Articles

Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma

Dharminder Chauhan, PhD, Ajita V. Singh, Mohan Brahmandam, Giada Bianchi, Klaus Podar, Teru Hideshima, Nikhil Munshi, Paul Richardson, Michael A. Palladino, PhD, Kenneth C. Anderson
Journal: Blood
Blood (2008) 112 (11): 3662.
https://doi.org/10.1182/blood.V112.11.3662.3662
Published: 2008
Journal Articles

Pharmacodynamic and Efficacy Studies of a Novel Proteasome Inhibitor NPI-0052 in Human Plasmacytoma Xenograft Mouse Model

Ajita V. Singh, G. Kenneth Lloyd, Michael A. Palladino, PhD, Dharminder Chauhan, Kenneth C. Anderson
Journal: Blood
Blood (2008) 112 (11): 3665.
https://doi.org/10.1182/blood.V112.11.3665.3665
Published: 2008
Journal Articles

Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL

Timothy Price, MD, Peeter Padrik, MD, Amanda Townsend, MD, Paul Mainwaring, MD, Lawrence Catley, MD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, Michael A. Palladino, PhD, G. Kenneth Lloyd, PhD, Matthew A. Spear, MD, Michael Millward, MD
Journal: Blood
Blood (2008) 112 (11): 4934.
https://doi.org/10.1182/blood.V112.11.4934.4934
Published: 2008
Journal Articles

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

Mario I. Vega, PhD, Melisa Martinez- Paniagua, Sara Huerta-Yepez, PhD., Eriko Suzuki, Kazuo Umezawa, Kam Yeung, Ph.D., Massimo Libra, Stavroula Baritaki, Michael A. Palladino, PhD, Benjamin Bonavida, PhD
Journal: Blood
Blood (2008) 112 (11): 4973.
https://doi.org/10.1182/blood.V112.11.4973.4973
Published: 2008
Journal Articles

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Paul A. Hamlin, MD, Carol Aghajanian, M.D., David Hong, M.D., Anas Younes, M.D., Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Matthew A. Spear, MD, Razelle Kurzrock, MD
Journal: Blood
Blood (2008) 112 (11): 4939.
https://doi.org/10.1182/blood.V112.11.4939.4939
Published: 2008
Journal Articles

Dual targeting of the proteasome regulates survival and homing in Waldenström macroglobulinemia

Aldo M. Roccaro, Xavier Leleu, Antonio Sacco, Xiaoying Jia, Molly Melhem, Anne-Sophie Moreau, Hai T. Ngo, Judith Runnels, Abdelkareem Azab, Feda Azab, Nicholas Burwick, Mena Farag, Steven P. Treon, Michael A. Palladino, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson, Irene M. Ghobrial
Journal: Blood
Blood (2008) 111 (9): 4752–4763.
https://doi.org/10.1182/blood-2007-11-120972
Published: 2008
Includes: Supplemental data
Journal Articles

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

Dharminder Chauhan, Ajita Singh, Mohan Brahmandam, Klaus Podar, Teru Hideshima, Paul Richardson, Nikhil Munshi, Michael A. Palladino, Kenneth C. Anderson
Journal: Blood
Blood (2008) 111 (3): 1654–1664.
https://doi.org/10.1182/blood-2007-08-105601
Published: 2008
Journal Articles

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Razelle Kurzrock, MD, Paul Hamlin, M.D., Anas Younes, M.D., David Hong, M.D., Michael Gordon, M.D., Matthew A. Spear, M.D., Michael A. Palladino, Ph.D., G. Kenneth Lloyd, Ph.D., Angie M. Longenecker, R.N., Saskia T.C. Neuteboom, Ph.D., Gillian F. Cropp, M.S., Alison Hannah, M.D., Carol Aghajanian, M.D.
Journal: Blood
Blood (2007) 110 (11): 4504.
https://doi.org/10.1182/blood.V110.11.4504.4504
Published: 2007
Journal Articles

Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB–regulated gene products

Kwang Seok Ahn, Gautam Sethi, Ta-Hsiang Chao, Saskia T. C. Neuteboom, Madan M. Chaturvedi, Michael A. Palladino, Anas Younes, Bharat B. Aggarwal
Journal: Blood
Blood (2007) 110 (7): 2286–2295.
https://doi.org/10.1182/blood-2007-04-084996
Published: 2007
Journal Articles

Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.

Dharminder Chauhan, PhD, Ajita Singh, Ph.D, Mugdha Velankar, M.S, Teru Hideshima, Ph.D, Huib Ovaa, Ph.D, Celia Berkers, M.S, Giada Bianchi, Ph.D, Roberto Sitia, M.D., Nikhil C. Munshi, M.D., Paul Richardson, M.D., Michael A. Palladino, Ph.D, Kenneth C. Anderson, M.D
Journal: Blood
Blood (2006) 108 (11): 3396.
https://doi.org/10.1182/blood.V108.11.3396.3396
Published: 2006